Integrity Advisory Solutions LLC Acquires Shares of 3,603 Amgen Inc. $AMGN

Integrity Advisory Solutions LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 3,603 shares of the medical research company’s stock, valued at approximately $1,017,000.

Several other large investors have also recently modified their holdings of AMGN. Brighton Jones LLC grew its position in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares in the last quarter. Schnieders Capital Management LLC. boosted its stake in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares during the period. Csenge Advisory Group grew its holdings in Amgen by 0.6% during the 2nd quarter. Csenge Advisory Group now owns 6,383 shares of the medical research company’s stock valued at $1,839,000 after buying an additional 40 shares in the last quarter. Finally, Asahi Life Asset Management CO. LTD. increased its position in shares of Amgen by 4.9% during the second quarter. Asahi Life Asset Management CO. LTD. now owns 9,312 shares of the medical research company’s stock valued at $2,600,000 after buying an additional 434 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board approved a $2.52 quarterly dividend, payable June 5, 2026, supporting income investors and signaling cash-flow confidence. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen launched a new Phase 3 subcutaneous trial to expand its blinatumomab franchise — a constructive pipeline development that could add long-term value if successful. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference on March 11; management comments (CFO and SVP of rare disease) could offer incremental guidance or pipeline color. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Coverage pieces examine post-earnings momentum and valuation (why AMGN has risen ~24% over the past year); useful for context but not single-driver news. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Neutral Sentiment: Reported short-interest data in early March appears erroneous (0 shares / NaN change); treat as noise until reliable data is posted. (No link available)
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals tying OX40 modulation to potential malignancies — this removes a late‑stage asset and raises near-term pipeline risk and uncertainty around R&D priorities. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: An analyst downgrade recommended waiting for a better entry point (rating cut / hold), which can amplify selling pressure after the pipeline news. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Trading Down 3.1%

NASDAQ AMGN opened at $367.60 on Friday. The stock has a market cap of $198.16 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 3.76 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The stock has a 50 day simple moving average of $352.53 and a two-hundred day simple moving average of $321.90. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen’s payout ratio is currently 70.84%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald raised their price objective on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Wells Fargo & Company raised their price target on shares of Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. Mizuho boosted their price target on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Leerink Partners reissued a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research note on Thursday. Finally, Scotiabank started coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $354.17.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.